Visão geral da empresa
A clinical-stage medical device enterprise, enVVeno Medical Corporation is dedicated to advancing the standard of care for venous disease through the development of bioprosthetic tissue-based solutions. The company operates within the Healthcare sector, specifically targeting the Medical Devices industry, which encompasses the creation and distribution of instruments, appliances, and equipment used in medical procedures. Currently, the organization employs a workforce of 33 individuals while maintaining a market capitalization of $6.77 million. These financial figures indicate that enVVeno is a micro-cap entity with limited revenue generation relative to its peer group, reflecting the typical early-stage characteristics of a clinical-stage development firm that prioritizes R&D over immediate commercial scale. The company's primary focus is the VenoValve, a replacement venous valve designed to treat venous insufficiency, yet its financial structure suggests significant investment is still required to transition from clinical trials to widespread market adoption.
Saúde financeira
The company reported a net income of $-19,472,000 and an EBITDA of $-20,763,000 for the trailing twelve-month period, with revenue figures listed as unavailable. The substantial gap between the reported net income and EBITDA, both of which are negative, reveals a cost structure dominated by high operating expenses likely associated with clinical trial costs, regulatory compliance, and R&D, which erode profitability before any commercial revenue is realized. Free cash flow stands at $-9,209,875, indicating that the company is currently burning cash rather than generating liquidity, which limits its immediate financial flexibility and necessitates reliance on external capital sources or cash reserves to fund operations. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which indicates that the company has not yet achieved commercial revenue or has recorded revenue that does not cover the direct costs of goods sold, consistent with a pre-revenue or early-revenue stage business model. On the balance sheet, the company holds $28.21 million in cash against $700,000 in debt, resulting in a debt-to-equity ratio of 2.58, which suggests a highly leveraged position relative to its equity base despite the absolute dollar amount of debt being low. However, the current ratio of 13.58 demonstrates an extremely strong short-term liquidity position, meaning the company possesses more than thirteen times the current assets needed to cover its current liabilities, providing a significant buffer against immediate financial distress. Return on Equity is -56.2% and Return on Assets is -35.1%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently in terms of profit generation, a common trait for development-stage biotech firms but a critical risk factor for mature investors.
Avaliação de valorização
The trailing P/E ratio is unavailable due to negative earnings, while the forward P/E is listed as -8.68, implying that the market prices the stock based on anticipated future profitability rather than historical performance. The price-to-book ratio is 0.25, indicating that the market values the company at a significant discount to its book value, which often occurs when intangible assets like intellectual property are not fully captured on the balance sheet or when the business carries substantial liabilities. The price-to-sales ratio is unavailable, and the EV/EBITDA stands at 1.00, suggesting a valuation that is theoretically low if earnings were positive, though the negative earnings render this metric less meaningful for traditional valuation comparisons. The stock has a 52-week high of $196.70 and a 52-week low of $8.67, placing the current trading price significantly below the historical peak and highlighting the extreme volatility experienced by the equity over the past year. The beta value is 1.09, which indicates that the stock price is slightly more volatile than the broader market, moving 9% more than the average market index in response to market-wide fluctuations.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as unavailable, preventing a direct comparison of earnings expansion relative to top-line growth rates. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, meaning the organization retains all available earnings and cash flow to reinvest into research, development, and clinical trial programs rather than distributing income to shareholders. Consequently, the company's growth profile is entirely dependent on successful product launches and regulatory approvals to convert its clinical-stage assets into commercial revenue streams that can sustain operations and reduce the current cash burn. The overall financial profile presents a high-risk, high-potential scenario typical of clinical-stage medical device companies, where value creation is contingent upon future commercial success rather than current income generation or dividend stability.